Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2113.29% is 31% above its 3-year average of -3044.77%, near the high end of its 3-year range (-10765.50%–71.30%).
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -10765.50%.
EBITDA MARGIN
-2113.29%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
-3044.77%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+30.59%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Zenas BioPharma, Inc.
Market Cap
$1.68B
EBITDA Margin
-2113.29%
TTM Avg
N/A
3Y Avg
-3044.77%
5Y Avg
N/A
Market Cap
$1.70B
EBITDA Margin
-112.01%
TTM Avg
-89.88%
3Y Avg
-115.02%
5Y Avg
-95.96%
Market Cap
$1.71B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.73B
EBITDA Margin
1.15%
TTM Avg
-0.80%
3Y Avg
-3.79%
5Y Avg
-4.67%
Market Cap
$1.73B
EBITDA Margin
12.70%
TTM Avg
1.17%
3Y Avg
-19.82%
5Y Avg
-118.23%
Market Cap
$1.74B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$1.62B
EBITDA Margin
19.54%
TTM Avg
15.33%
3Y Avg
15.07%
5Y Avg
12.91%
Market Cap
$1.62B
EBITDA Margin
-172.34%
TTM Avg
-3780.22%
3Y Avg
-1874.89%
5Y Avg
-1874.89%
Market Cap
$1.62B
EBITDA Margin
0.06%
TTM Avg
-4.29%
3Y Avg
-15.38%
5Y Avg
-22.40%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | $1.68B | -2113.29% | N/A | -3044.77% | N/A |
| Personalis, Inc. (PSNL)vs › | $1.70B | -112.01% | -89.88% | -115.02% | -95.96% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 16.41% | 1.22% | -1.65% | 4.31% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.73B | 1.15% | -0.80% | -3.79% | -4.67% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.73B | 12.70% | 1.17% | -19.82% | -118.23% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.74B | -628.14% | -766.74% | -948.44% | -801.32% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 19.54% | 15.33% | 15.07% | 12.91% |
| Septerna Inc (SEPN)vs › | $1.62B | -172.34% | -3780.22% | -1874.89% | -1874.89% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | 0.06% | -4.29% | -15.38% | -22.40% |
| Novocure Ltd (NVCR)vs › | $1.75B | -20.84% | -23.57% | -26.35% | -17.29% |
Gross Margin
100.0%
EBITDA Margin
-2113.3%
Operating Margin
-2113.8%
Net Margin
-48438.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -10765.50% |
| 2025-03-31 | -373.07% |
| 2024-12-31 | -1111.80% |
| 2023-09-30 | 71.30% |
